383 related articles for article (PubMed ID: 28935492)
21. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
Abrahamowicz M; Esdaile JM; Ramsey-Goldman R; Simon LS; Strand V; Lipsky PE
Arthritis Rheumatol; 2018 Sep; 70(9):1450-1458. PubMed ID: 29648686
[TBL] [Abstract][Full Text] [Related]
22. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.
Touma Z; Sayani A; Pineau CA; Fortin I; Matsos M; Ecker GA; Chow A; Iczkovitz S
Rheumatol Int; 2017 Jun; 37(6):865-873. PubMed ID: 28280970
[TBL] [Abstract][Full Text] [Related]
23. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
Staveri C; Karokis D; Liossis SC
Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
[TBL] [Abstract][Full Text] [Related]
24. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.
Parodis I; Sjöwall C; Jönsen A; Ramsköld D; Zickert A; Frodlund M; Sohrabian A; Arnaud L; Rönnelid J; Malmström V; Bengtsson AA; Gunnarsson I
Autoimmun Rev; 2017 Apr; 16(4):343-351. PubMed ID: 28216072
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A case series.
Fan Q; Yang H; Liu Y
Z Rheumatol; 2024 Jun; 83(5):387-392. PubMed ID: 38157053
[TBL] [Abstract][Full Text] [Related]
26. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R
BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520
[TBL] [Abstract][Full Text] [Related]
28. Smoking reduces the efficacy of belimumab in mucocutaneous lupus.
Parodis I; Gomez A; Frodlund M; Jönsen A; Zickert A; Sjöwall C; Bengtsson AA; Gunnarsson I
Expert Opin Biol Ther; 2018 Aug; 18(8):911-920. PubMed ID: 29958508
[TBL] [Abstract][Full Text] [Related]
29. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
van Vollenhoven RF; Petri MA; Cervera R; Roth DA; Ji BN; Kleoudis CS; Zhong ZJ; Freimuth W
Ann Rheum Dis; 2012 Aug; 71(8):1343-9. PubMed ID: 22337213
[TBL] [Abstract][Full Text] [Related]
30. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
Schwarting A; Dooley MA; Roth DA; Edwards L; Thompson A; Wilson B
Lupus; 2016 Dec; 25(14):1587-1596. PubMed ID: 27488472
[TBL] [Abstract][Full Text] [Related]
31. Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.
Furer V; Zisman D; Pokroy-Shapira E; Molad Y; Elkayam O; Paran D
Scand J Rheumatol; 2016; 45(2):103-6. PubMed ID: 26515057
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.
Wallace DJ; Ginzler EM; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Petri M; Fettiplace J; Roth DA; Ji B; Heath A
Arthritis Rheumatol; 2019 Jul; 71(7):1125-1134. PubMed ID: 30771238
[TBL] [Abstract][Full Text] [Related]
33. Anti-BLyS Treatment of 36 Israeli Systemic Lupus Erythematosus Patients.
Sthoeger Z; Lorber M; Tal Y; Toubi E; Amital H; Kivity S; Langevitz P; Asher I; Elbirt D; Agmon Levin N
Isr Med Assoc J; 2017 Jan; 19(1):44-48. PubMed ID: 28457114
[TBL] [Abstract][Full Text] [Related]
34. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
[No Abstract] [Full Text] [Related]
35. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.
Hui-Yuen JS; Reddy A; Taylor J; Li X; Eichenfield AH; Bermudez LM; Starr AJ; Imundo LF; Buyon J; Furie RA; Kamen DL; Manzi S; Petri M; Ramsey-Goldman R; van Vollenhoven RF; Wallace DJ; Askanase A
J Rheumatol; 2015 Dec; 42(12):2288-95. PubMed ID: 26523030
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies.
Trentin F; Gatto M; Zen M; Larosa M; Maddalena L; Nalotto L; Saccon F; Zanatta E; Iaccarino L; Doria A
Clin Rev Allergy Immunol; 2018 Apr; 54(2):331-343. PubMed ID: 29512034
[TBL] [Abstract][Full Text] [Related]
37. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
[TBL] [Abstract][Full Text] [Related]
38. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
Nikoloudaki M; Nikolopoulos D; Koutsoviti S; Flouri I; Kapsala N; Repa A; Katsimbri P; Theotikos E; Pitsigavdaki S; Pateromichelaki K; Bertsias A; Elezoglou A; Sidiropoulos P; Fanouriakis A; Boumpas D; Bertsias G
Front Immunol; 2022; 13():1074044. PubMed ID: 36685524
[TBL] [Abstract][Full Text] [Related]
39. Belimumab: review of use in systemic lupus erythematosus.
Boyce EG; Fusco BE
Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
[TBL] [Abstract][Full Text] [Related]
40. Potential and prognostic factor for belimumab-free remission in patients with systemic lupus erythematosus: a single-center retrospective analysis.
Nakai T; Fukui S; Ikeda Y; Shimizu H; Tamaki H; Okada M
Clin Rheumatol; 2020 Dec; 39(12):3653-3659. PubMed ID: 32577850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
